+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sexual & Reproductive Health Drugs Market - Global Forecast 2026-2032- Product Image
Sexual & Reproductive Health Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Sexual & Reproductive Health Drugs Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011672
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sexual & Reproductive Health Drugs Market is projected to reach USD 45.23 Billion in 2026. It is expected to continue growing at a CAGR of 10.67%, reaching USD 83.37 Billion by 2032.

Sexual and reproductive health drugs sit at the intersection of public health, specialty pharmaceuticals, primary care, and consumer access. The category spans hormonal and nonhormonal contraceptives, emergency contraception, fertility medicines, drugs for sexually transmitted infections, HIV prevention and treatment products used in sexual health programs, menopause and androgen-related therapies, and medicines supporting maternal health.

Demand is supported by verified structural drivers: persistent unmet need for contraception, rising STI surveillance in many high-income markets, expanded telehealth prescribing, and policy attention to maternal health and family planning. WHO recognizes access to contraception and STI prevention as core components of reproductive health, while UNFPA links reliable reproductive health commodity supply to lower unintended pregnancy and improved health outcomes. For manufacturers, distributors, payers, and providers, competitive advantage increasingly depends on evidence generation, regulatory agility, supply resilience, affordability, and trusted patient engagement.

Transformative Shifts Reshaping Sexual & Reproductive Health

The sexual and reproductive health drugs landscape is shifting from clinic-centered episodic care to hybrid, pharmacy-enabled, and digital-first reproductive health models. Regulatory decisions such as expanded access pathways for contraception in several markets, including over-the-counter availability for selected oral contraceptives in the United States, are changing how patients discover, purchase, and adhere to therapies.

Product innovation is also broadening. Long-acting reversible contraceptives, self-administered injectables, multipurpose prevention technologies, fertility support drugs, and updated STI treatment protocols are gaining attention as health systems prioritize convenience, adherence, and outcomes. At the same time, reproductive health policy remains uneven across jurisdictions, creating market fragmentation that requires localized evidence, compliant messaging, and robust channel strategies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across discovery, development, commercialization, and post-market safety in sexual and reproductive health drugs. AI-enabled screening can support identification of new nonhormonal contraceptive targets, optimize formulation development, and improve trial feasibility by analyzing epidemiology, eligibility criteria, recruitment patterns, and site performance.

In market operations, AI can strengthen demand planning for contraceptives and STI therapies, detect pharmacovigilance signals more rapidly, and personalize adherence support through compliant digital tools. However, reproductive health data are highly sensitive. Industry leaders must apply privacy-by-design, bias testing, explainable models, cybersecurity safeguards, and human clinical oversight to prevent inequitable recommendations, protect patients, and maintain regulatory trust.

Key Regional Insights Across Global Markets

Asia-Pacific represents a high-volume opportunity shaped by large reproductive-age populations, expanding private healthcare, national family planning programs, and growing fertility treatment demand in China, India, Japan, South Korea, and Australia. WHO and UNFPA data consistently show that contraceptive access, adolescent reproductive health, and maternal health remain policy priorities across the region. Access remains uneven across rural and lower-income communities, making affordability, provider education, quality-assured supply, and last-mile distribution central to sustainable growth.

North America is characterized by advanced prescribing infrastructure, strong clinical guideline adoption, telehealth growth, pharmacy access models, and active debate around reproductive health access. Latin America combines expanding pharmacy networks, public-sector procurement, and increasing women’s health awareness with persistent disparities in insurance coverage, adolescent access, and rural care delivery. Europe benefits from mature regulatory systems, strong pharmacovigilance, established contraception use, and broad clinical guideline integration, though country-level reimbursement, age-based coverage, and access rules differ considerably.

The Middle East is influenced by rising healthcare investment, private-sector expansion, insurance development, and culturally specific care pathways, particularly across GCC economies. Africa has substantial public health need and donor-supported procurement for contraception, HIV prevention, HIV treatment, and STI programs; sustainable growth depends on commodity security, localized manufacturing capacity, trained providers, adolescent-friendly services, and equitable access for underserved populations.

Key Group Insights for Strategic Market Planning

ASEAN markets show rising demand for accessible contraception, STI treatment, maternal health medicines, and fertility services as urbanization, pharmacy expansion, digital health adoption, and public health programs improve care pathways. Regulatory heterogeneity across ASEAN requires country-specific registration, pricing, distribution, and education strategies rather than a single regional model.

The GCC offers growth potential through healthcare modernization, insurance expansion, specialist women’s health services, and premium private care, but successful market entry depends on culturally appropriate positioning, physician-led education, and compliance with local registration requirements. The European Union provides scale through harmonized regulatory principles, centralized pharmacovigilance expectations, cross-border quality standards, and advanced health technology assessment practices, yet reimbursement and patient access decisions remain primarily national.

BRICS countries collectively shape volume and access priorities through large populations, domestic manufacturing capability, public-sector procurement, and expanding healthcare infrastructure, while G7 markets influence innovation standards, clinical evidence expectations, digital health governance, and pricing benchmarks. NATO countries overlap significantly with high-income regulated markets where supply-chain security, resilience planning, essential medicine availability, and crisis preparedness are increasingly important for reproductive health continuity.

Key Country Insights Across Priority Markets

The United States leads in innovation, telehealth adoption, pharmacy access models, clinical guideline development, and payer complexity, while Canada emphasizes public health integration, provincial reimbursement differences, and equitable access. Mexico and Brazil are important Latin American markets where public procurement, private pharmacies, national immunization and HIV/STI programs, and expanding women’s health awareness shape demand for sexual and reproductive health drugs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain demonstrate mature clinical systems, strong regulatory oversight, established contraception use, and variable reimbursement for contraceptive, fertility-related, menopause, and STI therapies. Russia remains influenced by domestic policy, local manufacturing priorities, evolving procurement practices, and changing trade dynamics that affect medicine availability and supply planning.

China and India are central to Asia-Pacific scale, with China combining large patient pools, policy attention to fertility and demographic change, and expanding assisted reproductive care, while India offers high-volume demand, domestic generics capacity, public health programs, and persistent access gaps in underserved communities. Japan, Australia, and South Korea represent advanced regulated markets where aging demographics, delayed parenthood, fertility treatment, menopause care, STI surveillance, and women’s health innovation support differentiated opportunities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based portfolio strategies that address contraception, STI management, HIV prevention and treatment within sexual health programs, fertility care, menopause health, androgen-related conditions, and maternal health as connected needs rather than isolated categories. Organizations that combine clinical evidence, affordability, patient-friendly delivery formats, and inclusive education will be better positioned in both mature and emerging markets.

Action should focus on resilient supply chains, diversified manufacturing, quality-assured procurement, transparent pharmacovigilance, culturally competent communication, and partnerships with pharmacies, telehealth platforms, public health agencies, clinicians, and payers. Leaders should also build AI governance frameworks before scaling digital tools, ensuring privacy, fairness, explainability, regulatory compliance, cybersecurity, and measurable patient benefit.

Research Methodology and Validation Approach

This executive summary is based on secondary research and market intelligence synthesis from authoritative public sources, including global health agencies, national regulators, clinical guideline bodies, peer-reviewed literature, public policy updates, epidemiological surveillance, and regulatory developments relevant to sexual and reproductive health drugs. Sources commonly used for validation include WHO, UNFPA, UNAIDS, CDC, FDA, EMA, national health ministries, and recognized scientific journals.

The methodology emphasizes triangulation across epidemiology, regulatory developments, access policies, product innovation, payer dynamics, clinical guidelines, pharmacovigilance requirements, and distribution channels. Insights are screened for relevance, recency, and consistency, with qualitative interpretation applied to regional, group, and country-level market factors while avoiding unsupported projections, market sizing, or market share claims.

Conclusion and Strategic Outlook

The sexual and reproductive health drugs market is evolving from a product-supply category into a broader access, outcomes, and patient-engagement ecosystem. Momentum is supported by unmet need, innovation in drug delivery and prevention, expanding pharmacy and telehealth channels, stronger STI and HIV program integration, and wider recognition of reproductive health as essential healthcare.

The strongest opportunities will favor organizations that can operate responsibly across diverse policy environments, protect sensitive health data, maintain reliable supply, and demonstrate real-world value. Evidence-led execution, regional localization, compliant digital engagement, and trusted partnerships will define sustainable leadership in sexual and reproductive health drugs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Sexual & Reproductive Health Drugs Market, by Drug Class
7.1. Introduction
7.2. Contraceptives
7.2.1. Implantable Contraceptives
7.2.2. Injectable Contraceptives
7.2.3. Intrauterine System
7.2.4. Oral Contraceptives
7.2.5. Transdermal Patches
7.3. Erectile Dysfunction Treatments
7.4. Fertility Drugs
7.4.1. GnRH Analogues
7.4.2. Gonadotropins
7.4.3. Ovulation Inducers
7.5. HIV Prevention Antiretrovirals
7.6. Hormonal Therapies
8. Sexual & Reproductive Health Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Hormonal
8.3. Non Hormonal
9. Sexual & Reproductive Health Drugs Market, by Prescription Status
9.1. Introduction
9.2. Over The Counter
9.3. Prescription
10. Sexual & Reproductive Health Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.3.1. Capsules
10.3.2. Powders
10.3.3. Tablets
10.4. Topical
10.5. Transdermal
11. Sexual & Reproductive Health Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Sexual & Reproductive Health Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Sexual & Reproductive Health Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Sexual & Reproductive Health Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Sexual & Reproductive Health Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie, Inc.
17.2. AstraZeneca plc
17.3. Aurobindo Pharma Limited
17.4. Bausch Health Companies Inc.
17.5. Bayer AG
17.6. Becton, Dickinson and Company
17.7. Bristol-Myers Squibb Company
17.8. C. H. Boehringer Sohn AG and Co. KG
17.9. Cepheid Inc. by Danaher Corporation
17.10. Cipla Limited
17.11. DiaSorin S.p.A.
17.12. Dynavax Technologies Corp.
17.13. Eli Lilly and Company
17.14. F. Hoffmann-La Roche AG
17.15. Gilead Sciences, Inc.
17.16. GlaxoSmithKline Plc
17.17. Hologic, Inc.
17.18. Inovio Pharmaceuticals Inc.
17.19. Lee Pharma Ltd.
17.20. Lupin Limited
17.21. Merck & Co., Inc.
17.22. Novartis AG
17.23. Pfizer, Inc.
17.24. Sanofi S.A.
17.25. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMPLANTABLE CONTRACEPTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMPLANTABLE CONTRACEPTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMPLANTABLE CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INJECTABLE CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL INTRAUTERINE SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INTRAUTERINE SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INTRAUTERINE SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ERECTILE DYSFUNCTION TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ERECTILE DYSFUNCTION TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ERECTILE DYSFUNCTION TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FERTILITY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FERTILITY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FERTILITY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GNRH ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GNRH ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GNRH ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GONADOTROPINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GONADOTROPINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GONADOTROPINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL OVULATION INDUCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL OVULATION INDUCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL OVULATION INDUCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HIV PREVENTION ANTIRETROVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HIV PREVENTION ANTIRETROVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HIV PREVENTION ANTIRETROVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HORMONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HORMONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HORMONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NON HORMONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NON HORMONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NON HORMONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 110. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 112. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 113. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 114. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 115. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 116. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 118. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 142. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 143. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 144. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 145. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 146. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 148. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 163. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 164. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 165. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 166. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 167. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 169. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 173. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 174. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 175. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 176. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 177. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 179. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 183. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 184. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 185. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 186. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 187. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 189. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 203. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 204. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 205. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 206. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 207. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 209. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 213. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 214. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 215. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 216. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 217. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 219. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 222. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 224. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 225. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 226. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 227. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 228. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 230. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 244. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 245. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 246. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 247. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 248. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 250. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 252. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 254. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 255. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 256. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 257. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 258. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 260. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 265. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 266. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 267. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 268. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 295. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 296. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 297. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 298. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 300. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 302. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 314. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2017-2032 (USD MILLION)
TABLE 315. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2017-2032 (USD MILLION)
TABLE 316. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 317. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 318. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 320. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SI

Companies Mentioned

  • AbbVie, Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG and Co. KG
  • Cepheid Inc. by Danaher Corporation
  • Cipla Limited
  • DiaSorin S.p.A.
  • Dynavax Technologies Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • Inovio Pharmaceuticals Inc.
  • Lee Pharma Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 45.23 Billion
Forecasted Market Value ( USD ) by 2032 $ 83.37 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Reproductive Health Supplements Market - Global Forecast 2026-2032 - Product Image

Reproductive Health Supplements Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
2026 Reproductive Health Services: Global Market Size & Growth Report with Updated Country Recession Risk Forecasts - Product Image

2026 Reproductive Health Services: Global Market Size & Growth Report with Updated Country Recession Risk Forecasts

  • Report
  • 45 Pages
  • Global
From
Women Digital Health Solution Market - Global Forecast 2026-2032 - Product Image

Women Digital Health Solution Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Contraceptive Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Contraceptive Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Contraceptive Market in Australia - Product Image

Contraceptive Market in Australia

  • Report
  • 150 Pages
  • Australia
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.